Intec Pharma has received a grant from The Michael J. Fox Foundation for Parkinson’s Research in the amount of $705,000. The grant will finance a pre-clinical safety trial using the company’s delayed release Accordion Pill Carbidopa/Levodopa developed for the treatment of Parkinson’s disease. Intec Pharma has completed successfully Phase II clinical studies in approximately 60 patients. In 2010, Intec performed a 3 month trial in pre-clinical models in which the safety of the Accordion platform was proven. Since the AP-CD/LD is intended for a twice a day dosing regimen on a long term basis (for many years), Intec will perform a longer trial using the AP-CD/LD. The Trial is expected to be completed during the first quarter of 2014.